Press coverage about XBiotech (NASDAQ:XBIT) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. XBiotech earned a daily sentiment score of 0.01 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.3517100661921 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

XBiotech (XBIT) opened at $3.97 on Tuesday. XBiotech has a 1 year low of $2.77 and a 1 year high of $20.18.

COPYRIGHT VIOLATION NOTICE: This report was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/11/14/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-xbiotech-xbit-share-price.html.

About XBiotech

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response.

Insider Buying and Selling by Quarter for XBiotech (NASDAQ:XBIT)

Receive News & Stock Ratings for XBiotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech Inc. and related stocks with our FREE daily email newsletter.